138 related articles for article (PubMed ID: 27058566)
1. The benefits and drawbacks of biosimilars.
Cronstein BN
Clin Adv Hematol Oncol; 2015 Oct; 13(10):639-41. PubMed ID: 27058566
[No Abstract] [Full Text] [Related]
2. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
Qureshi ZP; Nagai S; Bennett CL
JAMA Oncol; 2019 Mar; 5(3):297-298. PubMed ID: 30508013
[No Abstract] [Full Text] [Related]
4. Filgrastim for the treatment of hematopoietic acute radiation syndrome.
Farese AM; MacVittie TJ
Drugs Today (Barc); 2015 Sep; 51(9):537-48. PubMed ID: 26488033
[TBL] [Abstract][Full Text] [Related]
5. [Biosimilar drugs in oncology].
Levêque D
Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study.
Targhetta C; Baronciani D; Capasso M; Depau C; Tandurella I; Giuseppina Corona M; Angelucci E
Am J Hematol; 2016 Feb; 91(2):E7-8. PubMed ID: 26596244
[No Abstract] [Full Text] [Related]
7. Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.
Kobayashi T; Kamada I; Komura J; Toyoshima S; Ishii-Watabe A
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):917-924. PubMed ID: 28612945
[TBL] [Abstract][Full Text] [Related]
8. FDA advisers recommend approval of biosimilar filgrastim.
Traynor K
Am J Health Syst Pharm; 2015 Feb; 72(4):262, 264. PubMed ID: 25631830
[No Abstract] [Full Text] [Related]
9. Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.
Kozlowski S; Birger N; Brereton S; McKean SJ; Wernecke M; Christl L; Kelman JA
JAMA; 2018 Sep; 320(9):929-931. PubMed ID: 30193265
[TBL] [Abstract][Full Text] [Related]
10. Tbo-Filgrastim: A Review in Neutropenic Conditions.
Blair HA; Scott LJ
BioDrugs; 2016 Apr; 30(2):153-60. PubMed ID: 27023705
[TBL] [Abstract][Full Text] [Related]
11. The science of biosimilars.
Bourzac K
Cancer Discov; 2012 Apr; 2(4):295. PubMed ID: 22576194
[No Abstract] [Full Text] [Related]
12. [Biosimilars: assessment of efficacy, safety and cost].
Domínguez-Gil Hurlé A
Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
[TBL] [Abstract][Full Text] [Related]
13. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
14. Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice.
Argnani L; Broccoli A; Pellegrini C; Casadei B; Zinzani PL
Hematol Oncol; 2017 Dec; 35(4):918-920. PubMed ID: 27862141
[No Abstract] [Full Text] [Related]
15. First Pegfilgrastim Biosimilar Approved.
Aschenbrenner DS
Am J Nurs; 2018 Oct; 118(10):19-20. PubMed ID: 30260881
[No Abstract] [Full Text] [Related]
16. The advent of biosimilars for the treatment of diabetes: current status and future directions.
Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
[TBL] [Abstract][Full Text] [Related]
17. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
18. Provider barriers in uptake of biosimilars: case study on filgrastim.
Chang J; Karaca-Mandic P; Go RS; Schondelmeyer S; Weisdorf D; Jeffery MM
Am J Manag Care; 2023 May; 29(5):e155-e158. PubMed ID: 37229790
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity.
Borrega R; Cruz JP; Taylor P; Goncalves J
BioDrugs; 2019 Dec; 33(6):693-695. PubMed ID: 31654334
[No Abstract] [Full Text] [Related]
20. Infliximab or biosimilars in sarcoidosis; to switch or not to switch?
Veltkamp M; Drent M; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):280-3. PubMed ID: 26847093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
